NCT03049189: An ongoing trial by ITM Solucin GmbH
This trial is ongoing. It must report results 10 months, 3 weeks from now.
Full data
Full entry on ClinicalTrials.gov | NCT03049189 |
---|---|
Title | A Prospective, Randomised, Controlled, Open-label, Multicentre Phase III Study to Evaluate Efficacy and Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Targeted Molecular Therapy With Everolimus in Patients With Inoperable, Progressive, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumours of Gastroenteric or Pancreatic Origin (GEP-NET) |
Results Status | Ongoing |
ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
Start date | Feb. 2, 2017 |
Completion date | Dec. 31, 2024 |
Required reporting date | Dec. 31, 2025, midnight |
Actual reporting date | None |
Date last checked at ClinicalTrials.gov | Feb. 9, 2024 |
Days late | None |